918487-10-2 Usage
General Description
1-Butyl-4-iodo-1H-pyrazole is a chemical compound belonging to the class of organic compounds called halopyrazoles. This class of compounds are characterized by a pyrazole ring substituted by one or more halogen atoms. In the case of 1-Butyl-4-iodo-1H-pyrazole, the pyrazole ring (consisting of two nitrogen atoms and three carbon atoms in a five-membered ring structure) is substituted by an iodine atom on the 4th carbon and a butyl group on the 1st carbon. The notation 1H indicates the presence of hydrogen at position 1. Details regarding its properties, uses, and safety measures are not widely available due to its less common nature.
Check Digit Verification of cas no
The CAS Registry Mumber 918487-10-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,8,4,8 and 7 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 918487-10:
(8*9)+(7*1)+(6*8)+(5*4)+(4*8)+(3*7)+(2*1)+(1*0)=202
202 % 10 = 2
So 918487-10-2 is a valid CAS Registry Number.
918487-10-2Relevant articles and documents
ORGANIC COMPOUNDS
-
Page/Page column 37, (2014/05/24)
Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in animals and/or humans
S1P RECEPTORS MODULATORS AND THEIR USE THEREOF
-
Page/Page column 99, (2010/04/30)
The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.
